LEADER 00759nam0-22002891i-450-
001 990002571310403321
035   $a000257131
035   $aFED01000257131
035   $a(Aleph)000257131FED01
035   $a000257131
100   $a20000920d1964----km-y0itay50------ba
101 0 $aENG
200 1 $aConformal Mapping$fL. Bieberbach
210   $aNew York$cChelsea$d1964
215   $avi, 234 p.$d17 cm
610 0 $aAnalisi complessa
610 0 $aFunzioni di una variabile complessa
676   $a515
700  1$aBieberbach,$bL.$029720
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990002571310403321
952   $aMXIII-A-119$b1394$fMAS
959   $aMAS
996   $aConformal Mapping$9436434
997   $aUNINA
DB    $aING01

LEADER 00861nam0-22002771i-450 
001 990001624440403321
005 20190529131317.0
035   $a000162444
035   $aFED01000162444
035   $a(Aleph)000162444FED01
035   $a000162444
100   $a20030910d1978----km-y0itay50------ba
101 0 $aeng
200 1 $aExperimental autoimmune myasthenia gravis$epossible role of antiacetylcholine receptor antibodies in the appearance ofthe neuromuscular blockade$fAnne Zurn
210   $aZurich$cJ. Druck-Verlag$d1978
215   $a83 p.$d22 cm
610 0 $aBiochimica
676   $a574.192
700  1$aZurn,$bAnne$069395
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aLG
912   $a990001624440403321
952   $a60 OP. 113/1$b47303$fFAGBC
959   $aFAGBC
996   $aExperimental autoimmune myasthenia gravis$9366511
997   $aUNINA